ABBV AbbVie
- Official Name: ABBVIE INC.
- Headquarters: 1 N Waukegan Rd, NORTH CHICAGO, IL, 60064 US
- CEO: Robert A. Michael
- Website: abbvie.com
- Key Investor: VANGUARD GROUP INC | 9.85%
- Dedicated Investor: LIVELSBERGER FINANCIAL ADVISORY | 41.31%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-18 | 1 | Lost by 2.207 | (0.476) - 1.731 | ||
| 2025-07-25 | 2 | Lost by 2.940 | 0.566 - 3.506 | ||
| 2025-07-29 | 2R | Won by 0.614 | 2.272 - 1.658 | ||
| 2025-08-01 | 3 | Won by 11.730 | 2.032 - (9.698) | ||
| 2025-08-07 | 1R | Won by 0.838 | 1.321 - 0.483 | ||
| 2025-08-08 | 4 | Won by 2.815 | 4.828 - 2.013 | ||
| 2025-08-12 | 3R | Lost by 1.996 | (0.913) - 1.083 | ||
| 2025-08-15 | 5 | Won by 4.691 TOTW | 5.345 - 0.654 | ||
| 2025-08-20 | 1R | Won by 2.500 | 1.521 - (0.979) | ||
| 2025-08-21 | 2R | Lost by 2.166 | 0.257 - 2.423 | ||
| 2025-08-22 | 6 | Won by 1.330 | 1.715 - 0.385 | ||
| 2025-08-29 | 7 | Lost by 2.417 | (0.062) - 2.355 | ||
| 2025-09-03 | 2R | Won by 1.017 | (0.028) - (1.045) | ||
| 2025-09-05 | 8 | Lost by 0.428 | 0.975 - 1.403 | ||
| 2025-09-12 | 9 | Won by 3.532 | 2.886 - (0.646) | ||
| 2025-09-17 | 3R | Won by 4.204 | 2.133 - (2.071) | ||
| 2025-09-19 | 10 | Won by 0.067 | 1.810 - 1.743 | ||
| 2025-09-26 | 11 | Lost by 2.221 | (0.730) - 1.491 | ||
| 2025-10-01 | QF | Lost by 3.537 | 5.264 - 8.801 | ||
| 2025-10-03 | 12 | Won by 3.314 | 5.178 - 1.864 | ||
| 2025-10-10 | 13 | Lost by 0.085 | (1.328) - (1.243) | ||
| 2025-10-17 | 14 | Lost by 2.122 | (0.438) - 1.684 | ||
| 2025-10-24 | 15 | Lost by 2.163 | (0.664) - 1.499 |
Latest News
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?
Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth in important parts of the...
AbbVie vs. Merck: Which Pharma Stock Offers Better Value?
AbbVie Inc. (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) have something important in common that is important for investors, which is that both mu...
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
AbbVie Inc. (NYSE:ABBV) is delivering strong returns this year, with shares surging by over 23% year-to-date. In comparison, the broader market has re...
5 Stock Ideas for Your Short List
Forget the AI stocks. These five stocks have momentum right now.
Trade Tracker: Kevin Simpson buys AbbVie
Kevin Simpson, founder and CEO of Capital Wealth Planning, joins CNBC's 'Halftime Report' to detail his latest portfolio move. The Inve...
AbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News Lands
AbbVie has delivered strong share price gains in recent years, and the latest drug updates keep the story in the spotlight. The key issue for anyone l...
What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The EPCOR...
Gilead and Cardinal Health Stocks Jump to Record Highs. Why Healthcare Is on a Tear.
AbbVie, meanwhile, closed just shy of a record high, with shares ticking up 0.6% to $283.40.
How Has Merck's Story Changed?
Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand...
Cathie Wood-Backed Biotech IPO Pops in Debut
The IPO market may be in a bit of a slump as investors wait for Anthropic to finally file officially for a stock sale.
AbbVie’s Q3 2026 Earnings: What to Expect
Biopharma giant AbbVie is set to report its Q3 results on Oct. 30.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readout...
Where Could Johnson & Johnson's Next Growth Come From?
Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors pay...
Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaq
Hotter September inflation revived Fed hike bets and a Gartner warning crushed AI neoclouds. Pharma caught a bid, BlackRock hit a record, BofA got fin...
Why Eli Lilly Became Wall Street’s Safe Haven on a Hot CPI Day
Eli Lilly (LLY:NYSE) stock rose roughly 4% on Wednesday, October 14, joining a broad rally in healthcare stocks. No major Lilly news drove it.
What Could Send Regeneron Stock Higher?
Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying ...
Top S&P500 movers in Wednesday's session
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today.
Shares of Lilly, the world’s largest pharmaceutical company by market value, rallied above their 50-day moving average to mark their best level sinc...
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales...
Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?
Earlier this week, AbbVie reported Phase 3 AFFIRM data showing subcutaneous SKYRIZI induced endoscopic remission and ulcer-free endoscopy in a meaning...
The Open Question Under Johnson & Johnson Stock's Price
Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The...
Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Which Stock Wins?
Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choo...
Bet on These Healthcare ETFs to Benefit From the Aging US Population
With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-relat...
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this lis...
8 Of 11 Sectors Fall Wednesday As Defensives Lead
Three sectors are higher and eight are lower in Wednesday's regular session, with defensive sectors holding the top three positions. The leade...
1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face s...
Is Amgen Stock Worth More Than Its Competitors?
Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. ...
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
One faces patent cliffs and revenue concentration; the other dominates a booming market but trades at a premium valuation.
What Does Bristol-Myers Squibb Offer That Pfizer Does Not?
Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market ex...
What Is Eli Lilly Stock's Biggest Opportunity?
Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. ...
AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
AbbVie today announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with SKYRIZI® (risankizumab-rzaa) i...
5 High-Yield Dividend Stocks That Could Turn October’s Market Weakness Into Income
Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking n...
Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests
Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shar...
AbbVie Announces Data From Its Phase 3 AFFIRM Study Of SKYRIZI Demonstrates 35.8% Of Patients With Crohn's Disease Achieved Endoscopic Remission After Treatment
AbbVie today announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with SKYRIZI® (risankizumab-rzaa) ...
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
Alaunos Therapeutics acquired Velaris and raised $350 million to advance clinical therapies for pulmonary arterial hypertension through 2029.
Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?
Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.
Cyclicals Lead Sectors In Tuesday Trading As Health Care Trails
Four sectors are higher and seven are lower in Tuesday’s regular session, with cyclical sectors holding two of the top three positions. Materials si...
RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target
RBC Capital analyst Trung Huynh reiterates AbbVie (NYSE:ABBV) with a Outperform and maintains $280 price target.
Netflix, DocuSign And A Health Care Stock On CNBC’s ‘Final Trades’
CNBC traders picked Netflix, AbbVie and DocuSign, citing analyst support, strong momentum, breakthrough designations and a 10% FCF yield.
AbbVie (ABBV) Could Be 44% Below Fair Value On Fresh Pipeline Wins
How AbbVie’s latest data releases are reshaping the story AbbVie (ABBV) has packed the early October news cycle with fresh clinical data and regulat...
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
AbbVie (ABBV) reached $281.04 at the closing of the latest trading day, reflecting a +1.65% change compared to its last close.
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 throu...
Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the immunology mar...
Final Trades: Netflix, AbbVie and Docusign
The Investment Committee gives you their top stocks to watch for the second half.
Prediction: AbbVie’s Next Billion-Dollar Opportunity Is Taking Shape
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of...
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m. ET on Tuesday, October 20, 2026 to review the surabgene lomp...
Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI ve...
SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH
The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.